TIL — Instil Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1789769 ·
Last close
$5.40
Market Cap
$36.62M
52W High
$13.50
52W Low
$5.17
ADV30
66,658
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -6,066,000 | -4,231,000 | 195,645,000 | 2,544,000 | 93,081,000 |
| Jun 2026 | 0 | — | -5,400,000 | -4,299,000 | 197,712,000 | 5,541,000 | 90,332,000 |
| Mar 2026 | 0 | — | -6,018,000 | -4,204,000 | 200,428,000 | 5,022,000 | 89,730,000 |
| Dec 2025 | 0 | — | -9,557,000 | -8,191,000 | 203,523,000 | 6,638,000 | 89,657,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,612,000
Investing CF
$21,239,000
Financing CF
$378,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.50
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-734,991,000
Inventory
—
Receivables
$26,000
ST Investments
$64,137,000
EBIT TTM
$-24,982,000
Pretax Income TTM
$-30,281,000
Interest Exp TTM
$5,299,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -51,959,000 | -71,372,000 | 203,523,000 | 89,657,000 | 113,866,000 | -36,619,000 |
| Dec 2024 | 0 | -56,048,000 | -74,135,000 | 263,567,000 | 94,131,000 | 169,436,000 | -55,696,000 |
| Dec 2023 | 0 | -87,157,000 | -156,087,000 | 325,630,000 | 99,801,000 | 225,829,000 | -82,029,000 |
| Dec 2022 | 0 | -203,291,000 | -223,177,000 | 482,128,000 | 118,523,000 | 363,605,000 | -180,164,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-30,281,000
OpCashFlow TTM
—
Assets (Latest)
$197,712,000
Forward EPS
$-14.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | $36.81M | $0.34 | — |
| TVGN | Tevogen Inc. | $37.05M | $5.69 | — |
| BKHA | Black Hawk Acquisition Corp | $35.93M | $8.65 | — |
| ELUT | ELUTIA INC. | $37.91M | $0.85 | — |
| KLRS | Kalaris Therapeutics, Inc. | $34.04M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-16 12:00 · Yahoo
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:00 · Yahoo
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-13 21:00 · Yahoo
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-27 11:00 · Yahoo
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
2026-02-03 15:20 · Yahoo
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
2026-02-03 15:06 · Yahoo
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
2026-01-06 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.